- Joined
- Jan 3, 2009
- Messages
- 2,605
- Points
- 0
FDA-approved cancer drugs that may fight HIV identified
ANI
Washington, August 21, 2010
University of Minnesota researchers have identified two FDA approved drugs that may fight HIV. "HIV's ability to mutate makes it difficult to target and treat," said molecular virologist Louis Mansky. "We wanted to take advantage of this behaviour by stimulating HIV's mutation rate, essentially using the virus as a weapon against itself," Mansky added.
The two drugs, decitabine and gemcitabine - both FDA approved and currently used in pre-cancer and cancer therapy - were found to eliminate HIV infection in the mouse model by causing the virus to mutate itself to death - an outcome researchers dubbed "lethal mutagenesis."
Mansky and colleague Christine Clouser found that the drug concentrations needed to eliminate HIV infection cause no measurable cell toxicity and were effective against HIV cultures at concentrations well below the current levels used for cancer treatment.
Gemcitabine and decitabine have been administered in pre-clinical trials with mice.
Initial findings confirm that the drugs are an effective antiviral therapy for HIV.
The researchers are now in the process of modifying the drugs to forms that can be absorbed by the human body when taken orally.
The findings were recently published online in the Journal of Virology.
.
ANI
Washington, August 21, 2010
University of Minnesota researchers have identified two FDA approved drugs that may fight HIV. "HIV's ability to mutate makes it difficult to target and treat," said molecular virologist Louis Mansky. "We wanted to take advantage of this behaviour by stimulating HIV's mutation rate, essentially using the virus as a weapon against itself," Mansky added.
The two drugs, decitabine and gemcitabine - both FDA approved and currently used in pre-cancer and cancer therapy - were found to eliminate HIV infection in the mouse model by causing the virus to mutate itself to death - an outcome researchers dubbed "lethal mutagenesis."
Mansky and colleague Christine Clouser found that the drug concentrations needed to eliminate HIV infection cause no measurable cell toxicity and were effective against HIV cultures at concentrations well below the current levels used for cancer treatment.
Gemcitabine and decitabine have been administered in pre-clinical trials with mice.
Initial findings confirm that the drugs are an effective antiviral therapy for HIV.
The researchers are now in the process of modifying the drugs to forms that can be absorbed by the human body when taken orally.
The findings were recently published online in the Journal of Virology.
.
